Fulcrum Therapeutics, Inc.
FULCNASDAQHealthcareBiotechnology
As of Oct 15, 2026 close
- Market cap
- $279.89M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $2.83$15.74
- Volume (live)
- -
- Avg. volume (3M)
- 1.43M
Fulcrum Therapeutics (FULC) Stock Price & Financial Analysis
Fulcrum Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $3.66 - $3.73 |
|---|---|
| 52-Week High | $15.74 |
| 52-Week Low | $2.83 |
| Open | $3.71 |
| Volume (last close) | 1.23M |
| Average Volume (3M) | 1.43M |
| 50-Day MA | $3.78 |
|---|---|
| 200-Day MA | $6.27 |
| 1-Year Change | −60.50% |
| Market Cap | 279.89M |
|---|---|
| Shares Outstanding | 76.26M |
| Price to Book (P/B) | 0.90 |
| EV/EBITDA | -2.85 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Fulcrum Therapeutics at a Glance
As of the Oct 15, 2026 close, Fulcrum Therapeutics (FULC) has a market capitalization of $279.89M. Revenue fell 100.0% year over year.
As of its latest reported balance sheet, it holds $48.47M in cash and securities against $5.28M of debt, a net cash position of $43.19M.
Fulcrum Therapeutics does not currently pay a dividend.
The share price is down 60.5% over the past year. At $3.67 (the Oct 15, 2026 close) it sits near the bottom of its 52-week range of $2.83 to $15.74, below its 200-day moving average of $6.27.
Based on 2 professional analyst ratings from the past 90 days, the consensus is Sell with an average price target of $3.00, 18.3% below the Oct 15, 2026 close.
Frequently Asked Questions About Fulcrum Therapeutics
What is the current stock price for FULC?
As of the Oct 15, 2026 close, FULC stock trades at $3.67. The 52-week range is $2.83–$15.74, with a day range of $3.66–$3.73.
What is the P/E ratio for FULC?
The P/E ratio (Price-to-Earnings) for FULC is shown in the Key Statistics section. This valuation metric helps compare Fulcrum Therapeutics, Inc. to industry peers.
Does FULC pay dividends?
Fulcrum Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for FULC?
Based on ratings from 2 professional analysts over the last 90 days, the consensus for FULC is Sell. The average 12-month price target is $3.00, a 18.3% downside from the Oct 15, 2026 close of $3.67.
What is the market cap of FULC?
As of the Oct 15, 2026 close, Fulcrum Therapeutics's market capitalization is $279.9M, classifying it as a micro-cap company. Fulcrum Therapeutics operates in the Healthcare sector within the Biotechnology industry.